About this Journal Submit a Manuscript Table of Contents
Prostate Cancer
Volume 2011 (2011), Article ID 419174, 8 pages
http://dx.doi.org/10.1155/2011/419174
Review Article

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer

Division of Urology, Department of Surgery, University of Colorado Denver, Aurora, CO 80045, USA

Received 29 June 2010; Accepted 3 January 2011

Academic Editor: Manfred P. Wirth

Copyright © 2011 Kristene Myklak and Shandra Wilson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Quality of life has become increasingly more important for men diagnosed with prostate cancer. In light of this and the recognized risks of androgen deprivation therapy (ADT), the guidelines and use of ADT have changed significantly over the last few years. This paper reviews the current recommendations and the future perspectives regarding ADT. The benefits of ADT are evident neoadjuvantly and adjuvantly in patients treated with external beam radiation therapy for intermediate- and high-risk disease, in patients who have undergone prostatectomy with lymph node involvement, in high-risk patients after definitive therapy, and in patients who have developed progression or metastasis. Finally, this paper reviews the risks and benefits of each of these scenarios and the risks of androgen deprivation in general, and it delineates the areas where ADT was previously recommended, but where evidence is lacking for its additional benefit.